ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Infected total knee arthroplasty: could cotrimoxazole be the answer?
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aims of this study were to describe the microbiological profile and antibiotic susceptibility of acute and chronic prosthetic joint infection (PJI) after total knee arthroplasty (TKA) and to propose appropriate empirical antibiotics.
methodsWe performed a retrospective review using our institution's database to collect data from patients with PJI who underwent reoperation following a primary TKA, between 2021 and 2024. Demographic data, microbiological results and antimicrobial susceptibility testing were analysed.
resultsForty patients met the study criteria and were included in the study. Chronic infections (> 6 weeks after implantation) were the most common, accounting for 75% of the forty cases. Regardless of classification by time to infection, gram-positive organisms were the predominant causative agents. The most frequently identified pathogens were Staphylococcus aureus (24.2%), Staphylococcus epidermidis (16.7%) and Staphylococcus lugdunensis (13.6%). Vancomycin proved to be the most effective antimicrobial, with a susceptibility of 100% in all cases, in both acute and chronic infections. As for chronic infections, Cotrimoxazole (Sulfamethoxazole/Trimethoprim) demonstrated low levels of resistance, with 97% susceptibility among the main pathogens involved in these cases.
conclusionsThe choice of antibiotic for empirical treatment should consider the time since prosthesis implantation, as pathogen distribution and their susceptibilities differ slightly between acute and chronic infections. For acute infections, vancomycin should be considered the first-line treatment. In chronic infections, Cotrimoxazole may serve as a potential alternative treatment, due to its low resistance profile. Nevertheless, de-escalation to targeted therapy should be implemented as soon as the final culture results become available.
Indexed as
Identifiers
41264201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.